Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With or Without Metabolic Syndrome Risk Factors - A Study Protocol for a Double-blind, Randomised, Multi-center, Placebo-controlled Clinical Trial

Obesity Clinical Trial

Official title:

Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With or Without Metabolic Syndrome Risk Factors - A Study Protocol for a Double-blind, Randomised, Multi-center, Placebo-controlled Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03479346
• Other study ID #: ISEE_2017_GGT
• Status: Completed
• Phase: N/A
• Start date: April 28, 2018
• Est. completion date: December 1, 2020

Study information

• Verified date: April 2021
• Source: Gachon University Gil Oriental Medical Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Purpose of this trial is to investigate the efficacy and safety of GGT on Korean obese Women with or without metabolic syndrome Risk factors

Recruitment information / eligibility

• Status: Completed
• Enrollment: 140
• Est. completion date: December 1, 2020
• Est. primary completion date: October 1, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 19 Years to 65 Years

Eligibility

Inclusion Criteria:

• Female aged 19 to 65 years

• Subject must included at least one or more of the following symptoms below;

• BMI of 30 kg/? or more;

• BMI between 27 and 29.9kg/? with non-insulin-dependent diabetes mellitus, taking medication or fasting blood glucose > 126mg/dL at the screening visit

• BMI between 27 and 29.9kg/? with hyperlipidemia, taking medication or total cholesterol = 200mg/dL or Triglyceride = 150mg/dL at screening visit

• Agreed to low-calorie diet during the trial

• Written informed consent of the trial

Exclusion Criteria:

• Subjects who had experience with allergic reaction on investigational drug(any ingredients of IP)

• Subjects who has diabetes as comorbidity, had experienced the elevation of blood glucose by ephedrine

• Subjects who had experienced rash, rubefaction, or itchiness by GGT administration

• Subjects who usually feel fatigue due to hyperhidrosis

• Subjects who experienced other allergic reactions

• Subjects who had 10 percent reduction in body weight over 6 months

• Subjects who decided to quit smoking over the last 3 months or have irregular smoking habits

• Subjects who have endocrine diseases associated with weight gain, such as hypothyroidism, Cushing's syndrome, etc.

• Subjects who have heart disease (heart failure, angina pectoris, myocardial infarction)

• Subjects who have uncontrolled hypertension despite the use of antihypertensive drugs (SBP > 145 mmHg or DBP > 95 mmHg)

• Subjects who have uncontrolled diabetes despite the use of drugs (FBS>7.8 mmol/L (140 mg/dL))

• Subjects who have severe renal disability (SCr > 2.0 mg/dL)

• Subjects who have severe liver disability (2.5 fold of normal high range value on Alanine Aminotransferase [ALT], Aspartate Aminotransferase [AST], alkaline phosphatase [ALP])

• Subjects who have poor digestion(anorexia, stomach discomfort, nausea, vomiting etc) or have the history of eating disorder such as anorexia nervosa or bulimia nervosa, etc.(KEAT-26 < 20)

• Use of medication that can affect on weight within last 3 months (appetite suppressant, laxative, oral steroid, thyroid hormone, amphetamine, cyproheptadine, phenothiazine or medications can affect on absorption, metabolism, excretion)

• Use of CNS stimulant medication for weight loss

• Subjects who had a use of drugs that can increase blood pressure or heart rate within a week, such as, Decongestants, cough, cold, allergy treatments that include the ingredients of phenylpropanolamine, ephedrine, pseudoephedrine

• Forbidden treatment (Insulin, hypoglycemic agent, antidepressant, antiserotonin agent, barbiturate, antipsychotic, medication concerns of abuse)

• Subjects who have diseases that may occur hypokalemia (hypomagnesemia, Bartter syndrome, Gitelman syndrome, diseases that can cause high aldosteronism etc.) or have cardiac dysrhythmia

• Difficult to measure anthropometric dimensions because of anatomical change such as resection

• History of weight loss surgery, such as bariatric surgery, etc.

• Edema or dysuria

• Malignant tumour or lung disease

• Cholelithiasis

• History of narrow angle glaucoma

• Subjects who have nervous or psychological medical history or presently suffer from the following diseases: depression, manic disorder, bipolar disorder, schizophrenia, epilepsy, alcoholism, anorexia, hyperphagia, etc.

• Subjects who have history of stroke or temporary ischemic cardioplegia

• Subjects who are judged to be inappropriate for the clinical study by the researchers

• Women who were pregnant, lactating or have the chances of pregnancy who do not agree to proper contraception (birth-control pill, hormone implant, IUD, spermicide, condom, abstinence, etc.)

• Use of other investigational product within last 1 month

Related Conditions & MeSH terms

• Metabolic Syndrome
• Obesity
• Syndrome

Intervention

Drug:
• GGT
Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
• Placebo
Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.

Locations

Country	Name	City	State
Korea, Republic of	Gachon University Gil Oriental Medical Hospital	Incheon

Sponsors (5)

Lead Sponsor	Collaborator
Gachon University Gil Oriental Medical Hospital	DongGuk University, Dongsin University Oriental Hospital, Kyunghee University Medical Center, Wonkwang University Guangju Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Changes from baseline in Kellgren-Lawrence grade	Determination of patient's knee condition	baseline, 12 weeks
Primary	Changes from baseline in body weight	Estimated mean changes from baseline in body weight after 12 weeks of treatment.	baseline, 12 weeks
Secondary	Changes from baseline in body fat percentage	Estimated mean changes from baseline in body fat percentage at different time points during treatment period	baseline, 4,8,12 weeks
Secondary	Changes from baseline in fat mass	Estimated mean changes from baseline in fat mass at different time points during treatment period	baseline, 4,8,12 weeks
Secondary	Changes from baseline in Waist circumference	Estimated mean changes from baseline in Waist circumference at different time points during treatment period	baseline, 4,8,12 weeks
Secondary	Changes from baseline in Waist/hip ratio	Estimated mean changes from baseline in Waist/hip ratio at different time points during treatment period	baseline, 4,8,12 weeks
Secondary	Changes from baseline in Body mass index	Estimated mean changes from baseline in Body mass index at different time points during treatment period	baseline, 4,8,12 weeks
Secondary	Changes from baseline in Lipid profile	Estimated mean changes from first visit in Lipid profile after 12 weeks of treatment.	Screening visit, 12 weeks
Secondary	Changes from baseline in C-reactive protein (CRP)	Estimated mean changes from baseline in C-reactive protein (CRP) after 12 weeks of treatment.	baseline, 12 weeks
Secondary	Changes from baseline in blood glucose	Estimated mean changes from first visit in blood glucose after 12 weeks of treatment.	Screening visit, 12 weeks
Secondary	European Quality of life 5 Dimension(EQ5D)	EQ-5D is a tool developed for health-related quality of life (HRQoL) assessment, and is widely used in the health care sector. Scores range from -1, 'health worse than death' to 1, 'perfect health'. EQ-5D-5L has 5 dimensions covering current health status and functionality: mobility (M), self care (SC), usual activities (UA), pain/discomfort (PD), and anxiety/depression (AD), to be rated out of 5 grades (1, no problem; 2, slight problem; 3, some/moderate problem; 4, severe problem; 5, extreme problem).	baseline, 12 weeks
Secondary	Changes from baseline in serum leptin	Estimated mean changes from first visit in serum leptin after 12 weeks of treatment.	baseline, 12 weeks
Secondary	Korean version of Western Ontario and McMasters Universities Oateoarthritis Index	Determination of patient's knee function and pain	baseline, 12, 16 weeks
Secondary	cost per QALY(Quality Adjusted Life Years) gained	The cost per QALY gained is calculated according to normal health-economic evaluation models.	6 months or 1 year
Secondary	Economic evaluation (medical costs)	Economic evaluation of medical costs will be performed to assess cost-effectiveness of the 2 groups.	baseline, 4,8,12,16,20,24 weeks
Secondary	Economic evaluation (time-related costs)	Economic evaluation of time-related costs will be performed to assess cost-effectiveness of the 2 groups.	baseline, 4,8,12,16,20,24 weeks
Secondary	Economic evaluation (lost productivity costs)	Economic evaluation of lost productivity costs will be performed to assess cost-effectiveness of the 2 groups.	baseline, 4,8,12,16,20,24 weeks